第一創業(002797.SZ):11月母公司淨利3105.33萬元 同比增178.4%
格隆匯12月5日丨第一創業(002797.SZ)公佈,2019年11月,公司(母公司口徑)實現營收1.39億元,同比增長43.7%;淨利潤3105.33萬元,同比增長178.4%;1-11月公司(母公司口徑)實現營收14.32億元,同比增長24.6%;淨利潤3.27億元,同比增長8.43%;11月末淨資產87.98億元。
此外,境內全資證券子公司一創投行11月實現營收773.77萬元,淨虧損417.45萬元;1-11月實現營收2.14億元,淨利潤5544.51萬元;11月末淨資產4.78億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.